These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 25572435)

  • 1. AM841, a covalent cannabinoid ligand, powerfully slows gastrointestinal motility in normal and stressed mice in a peripherally restricted manner.
    Keenan CM; Storr MA; Thakur GA; Wood JT; Wager-Miller J; Straiker A; Eno MR; Nikas SP; Bashashati M; Hu H; Mackie K; Makriyannis A; Sharkey KA
    Br J Pharmacol; 2015 May; 172(9):2406-18. PubMed ID: 25572435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and non-invasive in vivo effects of the cannabinoid-1 receptor agonist AM841 on gastrointestinal motor function in the rat.
    Abalo R; Chen C; Vera G; Fichna J; Thakur GA; López-Pérez AE; Makriyannis A; Martín-Fontelles MI; Storr M
    Neurogastroenterol Motil; 2015 Dec; 27(12):1721-35. PubMed ID: 26387676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone (SAB378), a peripherally restricted cannabinoid CB1/CB2 receptor agonist, inhibits gastrointestinal motility but has no effect on experimental colitis in mice.
    Cluny NL; Keenan CM; Duncan M; Fox A; Lutz B; Sharkey KA
    J Pharmacol Exp Ther; 2010 Sep; 334(3):973-80. PubMed ID: 20571060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. (-)-7'-Isothiocyanato-11-hydroxy-1',1'-dimethylheptylhexahydrocannabinol (AM841), a high-affinity electrophilic ligand, interacts covalently with a cysteine in helix six and activates the CB1 cannabinoid receptor.
    Picone RP; Khanolkar AD; Xu W; Ayotte LA; Thakur GA; Hurst DP; Abood ME; Reggio PH; Fournier DJ; Makriyannis A
    Mol Pharmacol; 2005 Dec; 68(6):1623-35. PubMed ID: 16157695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic cannabinoid receptor 2 activation reverses paclitaxel neuropathy without tolerance or cannabinoid receptor 1-dependent withdrawal.
    Deng L; Guindon J; Cornett BL; Makriyannis A; Mackie K; Hohmann AG
    Biol Psychiatry; 2015 Mar; 77(5):475-87. PubMed ID: 24853387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cannabinoids & Stress: impact of HU-210 on behavioral tests of anxiety in acutely stressed mice.
    Kinden R; Zhang X
    Behav Brain Res; 2015 May; 284():225-30. PubMed ID: 25707713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antinociceptive effects of the non-selective cannabinoid receptor agonist CP 55,940 are absent in CB1(-/-) and not CB2(-/-) mice in models of acute and persistent pain.
    Sain NM; Liang A; Kane SA; Urban MO
    Neuropharmacology; 2009 Sep; 57(3):235-41. PubMed ID: 19538975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo pharmacology of synthetic olivetol- or resorcinol-derived cannabinoid receptor ligands.
    Cascio MG; Bisogno T; Palazzo E; Thomas A; van der Stelt M; Brizzi A; de Novellis V; Marabese I; Ross R; van de Doelen T; Brizzi V; Pertwee R; Maione S; Di Marzo V
    Br J Pharmacol; 2006 Oct; 149(4):431-40. PubMed ID: 16953186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of cannabinoid-1 and cannabinoid-2 receptors in septic ileus.
    Li YY; Li YN; Ni JB; Chen CJ; Lv S; Chai SY; Wu RH; Yüce B; Storr M
    Neurogastroenterol Motil; 2010 Mar; 22(3):350-e88. PubMed ID: 19840270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CB1 Knockout Mice Unveil Sustained CB2-Mediated Antiallodynic Effects of the Mixed CB1/CB2 Agonist CP55,940 in a Mouse Model of Paclitaxel-Induced Neuropathic Pain.
    Deng L; Cornett BL; Mackie K; Hohmann AG
    Mol Pharmacol; 2015 Jul; 88(1):64-74. PubMed ID: 25904556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents.
    Cluny NL; Vemuri VK; Chambers AP; Limebeer CL; Bedard H; Wood JT; Lutz B; Zimmer A; Parker LA; Makriyannis A; Sharkey KA
    Br J Pharmacol; 2010 Oct; 161(3):629-42. PubMed ID: 20880401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibiting fatty acid amide hydrolase normalizes endotoxin-induced enhanced gastrointestinal motility in mice.
    Bashashati M; Storr MA; Nikas SP; Wood JT; Godlewski G; Liu J; Ho W; Keenan CM; Zhang H; Alapafuja SO; Cravatt BF; Lutz B; Mackie K; Kunos G; Patel KD; Makriyannis A; Davison JS; Sharkey KA
    Br J Pharmacol; 2012 Mar; 165(5):1556-71. PubMed ID: 21883147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel orally available salvinorin A analog PR-38 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome.
    Sałaga M; Polepally PR; Sobczak M; Grzywacz D; Kamysz W; Sibaev A; Storr M; Do Rego JC; Zjawiony JK; Fichna J
    J Pharmacol Exp Ther; 2014 Jul; 350(1):69-78. PubMed ID: 24891526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Functionalized Cannabinoid Receptor Probes: Development of Exceptionally Potent Agonists.
    Jiang S; Iliopoulos-Tsoutsouvas C; Tong F; Brust CA; Keenan CM; Raghav JG; Hua T; Wu S; Ho JH; Wu Y; Grim TW; Zvonok N; Thakur GA; Liu ZJ; Sharkey KA; Bohn LM; Nikas SP; Makriyannis A
    J Med Chem; 2021 Apr; 64(7):3870-3884. PubMed ID: 33761251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of cannabinoid receptor 2 reduces inflammation in acute experimental pancreatitis via intra-acinar activation of p38 and MK2-dependent mechanisms.
    Michler T; Storr M; Kramer J; Ochs S; Malo A; Reu S; Göke B; Schäfer C
    Am J Physiol Gastrointest Liver Physiol; 2013 Jan; 304(2):G181-92. PubMed ID: 23139224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antinociceptive effects of central administration of the endogenous cannabinoid receptor type 1 agonist VDPVNFKLLSH-OH [(m)VD-hemopressin(α)], an N-terminally extended hemopressin peptide.
    Han ZL; Fang Q; Wang ZL; Li XH; Li N; Chang XM; Pan JX; Tang HZ; Wang R
    J Pharmacol Exp Ther; 2014 Feb; 348(2):316-23. PubMed ID: 24307201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Up-regulation of immunomodulatory effects of mouse bone-marrow derived mesenchymal stem cells by tetrahydrocannabinol pre-treatment involving cannabinoid receptor CB2.
    Xie J; Xiao D; Xu Y; Zhao J; Jiang L; Hu X; Zhang Y; Yu L
    Oncotarget; 2016 Feb; 7(6):6436-47. PubMed ID: 26824325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of primary sensory neurone cannabinoid type-1 receptors in pain and the analgesic effects of the peripherally acting agonist CB-13 in mice.
    Ford NC; Barpujari A; He SQ; Huang Q; Zhang C; Dong X; Guan Y; Raja SN
    Br J Anaesth; 2022 Jan; 128(1):159-173. PubMed ID: 34844727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The novel peripherally active cannabinoid type 1 and serotonin type 3 receptor agonist AM9405 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome.
    Salaga M; Binienda A; Tichkule RB; Thakur GA; Makriyannis A; Storr M; Fichna J
    Eur J Pharmacol; 2018 Oct; 836():34-43. PubMed ID: 30121173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contrasting effects of different cannabinoid receptor ligands on mouse ingestive behaviour.
    Grey J; Terry P; Higgs S
    Behav Pharmacol; 2012 Sep; 23(5-6):551-9. PubMed ID: 22772336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.